Post-ASH 2020 Virtual iwAL Workshop Presentations

The Post-ASH 2020 Virtual iwAL Workshop took place between the 21^st and 22^nd of January 2021 with VJHemOnc as an official media partner.

This workshop highlighted key data in acute leukemias presented at the annual ASH 2020 meeting and featured important discussions on translating results into clinical practice.

Topics covered include MRD, CAR T-cell therapies and immunotherapy in ALL, and immunotherapy, FLT3, novel therapies, and controversies in AML.

MRD/Translational Research in ALL CAR-T in ALL Immunotherapy in ALL Immunotherapy in AML FLT3 in AML Controversies in AML Novel Therapies in AML & BPDCN

Day One – Acute Lymphoblastic Leukemia

Measurable residual disease, CAR T-cell therapies and immunotherapy

Session I: MRD/Translational Research in ALL

Monitoring MRD using peripheral blood in ALL

Lori Muffly Stanford University, Stanford University, CA, United States

Ultrasensitive NGS-based MRD assessment in Ph-negative ALL

Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Prognostic significance of genetic alterations in patients with Ph-positive ALL treated with hyper-CVAD plus dasatinib or hyper-CVAD plus ponatinib

Outcomes of adults with relapsed T-ALL included in MRD-oriented trials

Josep-Maria Ribera Germans Trias i Pujol University Hospital, Barcelona, Spain

Session I: Discussion

An insightful discussion on measurable residual disease and how this is used in patients with ALL chaired by Sabina Chiaretti of the University of Rome, Rome, Italy & Dieter Hoelzer of the University of Frankfurt, Frankfurt, Germany.

Session II: CAR-T in ALL

24-hour manufacture of anti-CD19/CD22 dual CAR T-Cell Therapy for B-ALL

Peihua Lu Lu Daopei Hospital, Beijing, China

ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in R/R
B-ALL and other B-cell malignancies

Claire Roddie University College London, London, United Kingdom

Safety and efficacy of a CRISPR/Cas9-engineered universal CAR-T cell Product (CTA101) in patients with R/R B-ALL

He Huang Zhejiang University, Hangzhou, China

Safety and efficacy of CD19 CAR T-Cells for pediatric relapsed ALL with active CNS involvement

Session II: Discussion

Noelle Frey, of the University of Pennsylvania, Philadelphia, PA, & Bijal Shah, of the Moffit Cancer Center, Tampa, FL, chair the discussion session on the use of CAR T-cell therapies in the treatment of ALL

Session III: Immunotherapy in ALL

Superior event-free survival with blinatumomab vs chemo in children with high-risk first relapse of B-cell ALL : randomized, controlled Phase III trial

Franco Locatelli IRCCS Ospedale Bambino Gesù, Rome, Italy

Session III: Discussion

The latest updates from ASH 2020 on the use of immunotherapy in ALL is discussed by our panellists and chaired by Daniel DeAngelo, of the Dana-Farber Cancer Institute, Boston, MA & Nicola Goekbucket of the University Hospital Frankfurt, Frankfurt, Germany

Day Two – Acute Myeloid Leukemia

Immunotherapy, FLT3-mutated AML & novel therapies

Session IV: Immunotherapy in AML

The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Flotetuzumab as salvage therapy for primary induction failure and early relapse AML

Ibrahim Aldoss City of Hope, Duarte, CA, United States

Complete responses in R/R AML patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody

Farhad Ravandi MD Anderson Cancer Center, Houston, TX, United States

Safety and efficacy of decitabine plus ipilimumab in R/R MDS/AML in the
post-BMT or transplant naïve settings

Jacqueline Garcia Dana-Farber Cancer Institute, Boston, MA, United States

Session IV: Discussion

Bob Lowenberg, of Erasmus MC Cancer Institute, Rotterdam, Netherlands, & Marion Subklewe, of LMU Hospital Munich, Munich, Germany, are joined by panellists to discuss novel immunotherapy approaches in AML.

Session V: FLT3 in AML

Phase I study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: final results

Keith Pratz University of Pennsylvania, Philadelphia, PA, United States

Efficacy and safety of venetoclax in combination with gilteritinib for R/R
FLT3-mutated AML in the expansion cohort of a Phase Ib study

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Clinical outcomes in patients with R/R AML treated with gilteritinib who received prior midostaurin or sorafenib

Alexander Perl University of Pennsylvania, Philadelphia, PA, United States

Patterns of secondary resistance differ in patients with AML treated with type I versus type II FLT3-inhibitors

Musa Yilmaz University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session V: Discussion

Updates on the use of FLT3-targeting therapies in FLT3-mutated AML from ASH 2020 is discussed by chairs Mark Levis, of Johns Hopkins Medicine, Baltimore, MD, and Naval Daver, of the MD Anderson Cancer Center, Houston, TX.

Session VI: Controversies in AML

CC-486 prolongs survival in patients with AML in remission after intensive chemo independent of MRD: QUAZAR AML-001 maintenance trial

Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States

CC-486 improves OS & RFS for AML patients in remission after intensive chemo, regardless of amount of consolidation: QUAZAR AML-001 maintenance trial

Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Molecular predictors and effectiveness of MRD eradication with chemotherapy and allogeneic stem cell transplantation for AML

Remission & survival after single vs. double induction with 7+3 for newly diagnosed AML: planned interim analysis of the SAL-Daunodouble trial

Christoph Röllig University Hospital Carl Gustav Carus, Dresden, Germany

Session VI: Discussion

This discussion addresses controversies in the management of AML and is chaired by Andrew Wei, of Alfred Hospital and Monash University, Melbourne, Australia & of the MD Anderson Cancer Center, Houston, TX.

Session VII: Novel Therapies in AML & BPDCN

Preliminary data on a Phase I/IIa first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with R/R AML

Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

5-year final results of CPX-351 vs 7+3 in older adults with newly diagnosed high-risk/secondary AML: outcomes by age subgroup and responders

Jeffrey Lancet H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Venetoclax with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or R/R AML

Curtis Lachowiez University of Texas MD Anderson Cancer Center, Houston, TX, United States

Initial results from a biomarker-directed Phase II trial of SY-1425, a potent and selective RARα agonist, in combination with azacitidine in R/R AML

Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate in patients with R/R blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session VII: Discussion

A thoughtful discussion on novel therapies and key updates in the management of AML and BPDCN chaired by Gail Roboz, of Weill Cornell Medicine, New York, NY & Courtney DiNardo, of the MD Anderson Cancer, Houston, TX.